3 of the Best Growth Stocks to Buy for Less Than $100 Right Now

The article identifies Netflix, Uber and Novo Nordisk as long-term value opportunities after double-digit share-price declines, citing discounted valuations and growth catalysts. Netflix is down 17% this year and trades at 25x trailing earnings; Uber is down about 18% over the past year, trades near $76 at 17x earnings, and generated more than $55B of trailing-12-month revenue and $9.6B of net income. Novo Nordisk trades near $47 at 11x earnings with a roughly 3.9% yield, while the thesis hinges on its ability to compete in the GLP-1 market despite Eli Lilly's lead.

Analysis

The article’s quoted prices and valuation metrics appear internally unreliable relative to current market conventions, so they should not be used for sizing or entry levels. That matters most for NFLX and UBER, where a seemingly modest earnings multiple can conceal materially different economics: NFLX’s upside depends on advertising and live-content monetization exceeding incremental sports/content amortization, while UBER’s robotaxi partnerships may initially defend rider liquidity but ultimately pressure take rate if autonomous-fleet operators gain bargaining power.

For NVO, the relevant debate is not whether GLP-1 demand remains large, but whether NVO can stabilize share and net price realization while capacity expands. LLY’s manufacturing execution, payer formulary positioning, and next-generation obesity pipeline create a risk that NVO’s low multiple reflects a structurally lower terminal margin rather than temporary sentiment; conversely, any evidence of improved prescription share or supply availability could drive a rapid multiple re-rating over the next 1-3 quarters.

The non-obvious second-order implication is that broad robotaxi adoption is more ambiguous for UBER than the market narrative suggests. UBER benefits if it remains the demand aggregator and avoids fleet capex, but its high-margin marketplace economics are vulnerable if Waymo, Tesla, or fleet owners control both supply and consumer acquisition. For NFLX, the key competitive risk is not subscriber churn alone but bidding inflation for sports rights, which could shift the company from a scalable software-like earnings narrative toward a more cyclical content-cost model over 6-18 months.

Key Decisions for Investors

• Do not initiate directional positions from the article’s stated prices or P/E ratios; verify live valuation, consensus EPS revisions, and short interest before acting. Treat discrepancies as a data-quality flag rather than a valuation signal.
• Watch NVO / LLY as a 3-6 month relative-value trade: go long NVO and short LLY only if NVO demonstrates sequential improvement in obesity-drug volume/share while LLY’s revenue revisions flatten. Target 15-20% relative upside; exit if NVO cuts full-year obesity guidance, loses major formulary access, or LLY extends supply-led share gains.
• Maintain a cautious neutral-to-underweight stance on UBER into robotaxi rollout milestones. A long UBER position is justified only if management demonstrates that autonomous rides preserve marketplace take rate and contribution profit; otherwise, consider UBER versus a basket of autonomous-technology beneficiaries as a hedge against platform disintermediation over 6-18 months.
• For NFLX, wait for evidence that advertising revenue and live programming improve operating-margin guidance without accelerating cash content commitments. A break in forward operating-margin estimates or a major sports-rights bid would falsify the margin-expansion thesis and favor a tactical short versus DIS or WBD only after confirming current relative valuations.